Align Technology (ALGN) Projected to Post Earnings on Wednesday

Align Technology (NASDAQ:ALGN) is anticipated to issue its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of $2.38 per share and revenue of $980.7470 million for the quarter. Align Technology has set its Q3 2025 guidance at EPS.Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 EPS for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.06 billion. Align Technology had a net margin of 11.04% and a return on equity of 13.36%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the firm earned $2.41 EPS. On average, analysts expect Align Technology to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Align Technology Stock Down 0.6%

ALGN stock opened at $135.21 on Monday. The company has a market cap of $9.80 billion, a PE ratio of 22.80, a price-to-earnings-growth ratio of 1.53 and a beta of 1.70. The business has a 50-day simple moving average of $134.14 and a 200 day simple moving average of $162.78. Align Technology has a 52 week low of $122.00 and a 52 week high of $246.19.

Align Technology declared that its Board of Directors has approved a stock buyback program on Tuesday, August 5th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the medical equipment provider to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Activity

In other news, CEO Joseph M. Hogan acquired 7,576 shares of the stock in a transaction dated Friday, August 1st. The stock was bought at an average price of $131.49 per share, with a total value of $996,168.24. Following the completion of the purchase, the chief executive officer directly owned 184,945 shares of the company’s stock, valued at $24,318,418.05. This represents a 4.27% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.66% of the stock is owned by corporate insiders.

Institutional Trading of Align Technology

Several institutional investors have recently added to or reduced their stakes in ALGN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Align Technology by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,222 shares of the medical equipment provider’s stock valued at $1,624,000 after acquiring an additional 469 shares during the last quarter. Focus Partners Wealth boosted its holdings in Align Technology by 5.2% in the first quarter. Focus Partners Wealth now owns 3,062 shares of the medical equipment provider’s stock valued at $486,000 after acquiring an additional 151 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Align Technology in the second quarter valued at approximately $204,000. EverSource Wealth Advisors LLC boosted its holdings in Align Technology by 55.7% in the second quarter. EverSource Wealth Advisors LLC now owns 531 shares of the medical equipment provider’s stock valued at $101,000 after acquiring an additional 190 shares during the last quarter. Finally, First Trust Advisors LP boosted its holdings in Align Technology by 201.7% in the second quarter. First Trust Advisors LP now owns 88,270 shares of the medical equipment provider’s stock valued at $16,712,000 after acquiring an additional 59,010 shares during the last quarter. 88.43% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ALGN has been the subject of several research analyst reports. Mizuho lowered their target price on Align Technology from $210.00 to $170.00 and set an “outperform” rating for the company in a research note on Monday, October 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of Align Technology in a research note on Friday. Stifel Nicolaus lowered their target price on Align Technology from $275.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, July 31st. Morgan Stanley lowered their target price on Align Technology from $154.00 to $142.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 21st. Finally, Wells Fargo & Company lowered their target price on Align Technology from $246.00 to $199.00 and set an “overweight” rating for the company in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $173.09.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.